About
About EMIG
EMIG is a pharmaceutical trade association representing the interests of a diverse range of life science companies operating in the UK. We engage with Government, politicians and those senior stakeholders who shape the licensing, value assessment and access of new medicines and innovative technologies to patients.
The EMIG flat fee and one vote for each Full Member company means that everyone is equal and this principle removes the politics of size in our organisation. Everyone has an equal say and opportunity to shape our policies. This makes policy easier to develop and faster to deliver.
We have c. 1,500 individual Member company colleagues registered as part of our Network. Our Membership includes:
- Large and small pharma
- A wide range of skilled Associate Members
- Patient Charities, Research Policy organisations and Universtities and Research Institutes - all of whom enjoy free Associate Membership
This means we have a vast knowledge base that can be accessed by Members to help other Members - Full or Associate. Anyone can ask our Network for help or advice anonymously by simply posting a question via our EMIG web portal. All the answers/responses are stored on the web portal and are freely available to Members
Our Story
Originally a networking group for senior executives in the pharmaceutical industry, EMIG has evolved over the years into an influential UK trade association representing the interests of small and medium-sized pharmaceutical companies.
EMIG works closely with the Department of Health and Social Care (DHSC), the Health Research Authority (HRA) MHRA, NICE, the extended UK HTA bodies and, importantly, the NHS.
EMIG started with 17 companies in 2005 and, today EMIG has 250+ member companies and organisations. Most of our Steering Group, have been part of EMIG since the beginning.
- 2005
- EMIG founded with 17 companies in response to the adverse outcome of the PPRS (the precursor of the VPAG).
- 2008
- EMIG grows to 80 member companies and is appointed to the board of EUCOPE, gaining a voice in Europe.
- 2009
- EMIG establishes 6 special interest groups and launches the EMIG Network.
- 2010
- New Conservative government under David Cameron reorganises the NHS, with primary care holding 70% of the health budget.
- 2013
- New PPRS – not a good deal for anyone.
- 2014
- NICE introduces two new “value elements”: burden of illness and wider societal impact.
- 2016
- The UK votes to leave the EU; EMIG membership reaches 170 companies and organisations.
- 2021
- The UK leaves the EU; the pharmaceutical industry faces challenging changes to trans-European licensing and business. EMIG membership grows to 210.
- 2023
- VPAS rebate hits 26.5%, creating a challenging commercial environment. EMIG membership grows to 230.
- 2024
- EMIG joins the VPAG operations board and the UK medicines and medical devices steering group. Membership grows to 240.
- 2025
- Membership grows to 250. The industry faces further challenges from the 2024 VPAG rebate.
Our Team
Leslie Galloway
Chairman
Leslie built a successful career of 50 years in senior management roles in both the pharmaceutical and medical device industries, culminating in the successful turnaround of a pharmaceutical business.
He was elected EMIG Chairman in 2005 and has been instrumental in the metamorphosis of EMIG from being a business/networking group to the influential trade association it is today.
He has published numerous articles, is a frequent speaker at national and international seminars, a Member of MENSA and is a visiting lecturer at the University of Cambridge.
Jill Payne
Administrator and Event Manager
Jill joined the team in 2016 and the industry in 1985 where she has held a number of roles in clinical research, data management, network and event management.
Jill is the person to go to if you have a query.
Steering Group
Abid Karim
Vice Chairman, Head of Europe Biocryst Pharma
Paul Ranson
EMIG Legal Advisor Morgan Lewis & VWV
Andy Farrant
General Manager Luye Pharma
Bruce Faulkner-Dunkley
Consultant
Robyn Hughes
Consultant
Eric Lowe
Consultant Eric Low Consulting and Ex Myeloma UK
Charlotte Phelps
Global CEO Nordic Pharma
Stuart Rose
CEO OBN
David Trevor
Start-up Consultant
Derek Williams
CEO Pantheon Consultancy
EMIG is represented on the following:
DHSC
The Department of Health & Social Care in London is a ministerial department responsible, inter alia, for England's NHS, the health of the nation and access to medicines. EMIG works closely with the Department on issues such as medicines supply and pricing.MHRA
The Medicines and Healthcare Regulatory Authority is responsible to the DHSC for ensuring that medicines and medical devices in the UK work and are acceptably safe. EMIG works closely with the MHRA, HTA agencies and the NHS to ensure the prompt availability of new medicines to patients.AWTTC
The All Wales Therapeutics and Toxicology Centre advise on new medicines to ensure they are used effectively and appropriately in Wales and EMIG has a seat on the AWTTC Committee.EUCOPE
The European Confederation of Pharmaceutical Entrepreneurs has been the voice of small and mid-sized pharmaceutical and biotech companies in Europe for the last 15 years. EMIG has been part of EUCOPE from the outset and Leslie Galloway is Vice president of the Board.